Molecular Partners’ R&D Day in New York highlights progress of pipeline of DARPin® therapeutic candidates and dedicated research focus areas

Zurich-Schlieren, Switzerland, and New York, December 6, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together with its partner Allergan.
On its R&D Day in New York, entitled “Building Tomorrow’s Breakthroughs,” the company elaborates
on its refined development plans for its most advanced proprietary candidate MP0250 in multiple
myeloma (MM). In particular, the company announces its intention to initiate a second phase 2 trial
for MP0250 in MM. This complementary trial will recruit patients with relapsed or refractory MM
who have failed at least two lines of therapy including a proteasome inhibitor and an
immunomodulatory drug (IMiD) and in whom the most recent therapy was IMiD-based. Patients will
be treated with MP0250 in combination with Pomalidomide® and dexamethasone. The design of the
initial phase 2 trial for MP0250 in MM will be updated to recruit patients with a proteasome inhibitor
(PI) based regimen as the most recent therapy. Those patients continue to be dosed with MP0250 in
combination with Velcade® and dexamethasone.
Molecular Partners also presents additional preclinical data on MP0310, its most advanced multispecific (FAP x 4-1BB) DARPin® immuno-oncology compound, which is expected to move into the clinic in 2019. In addition, data on FAP x CD40, a second multi-specific preclinical DARPin® therapeutic in immuno-oncology, will be presented.

  • The company announces plans to launch a second phase 2 clinical trial in multiple
    myeloma with MP0250, its proprietary lead asset in oncology
  • Pamela Trail, the company’s new CSO, highlights progress focusing the research
    team in several key areas, with the goal of producing a sustainable pipeline of
    DARPin® molecule IND candidates
  • The company provides additional insight on its immuno-oncology DARPin® toolbox,
    including MP0310 and a second multi-specific DARPin® molecule
  • Allergan reiterates its commitment to abicipar which has shown in phase 3 trials
    the potential to be the first fixed 12 week anti-VEGF for wet AMD

Media release